Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 4/2021

01-05-2021

Mutations in inherited fibrinogen disorders correlated with clinical features in the Chinese population

Authors: Yafang Wan, Tian Li, Wei Zhang, Liying Wang, Yu Zhang, Pu Liao, Shiqiang Liu

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2021

Login to get access

Abstract

Two probands with unknown reasons for low fibrinogen activity were considered to investigate the association between mutations in inherited fibrinogen disorders (IFDs) and clinical features in the Chinese population. A routine coagulation test was conducted on a Sysmex CS5100 coagulation analyzer, and Sanger sequencing was employed to analyze mutations. A PubMed database search through May 2020 was performed to identify relevant studies regarding the congenital fibrinogen disorder epidemic in China. A common heterozygous missense mutation (c.1233G > A p.Arg35His), a novel heterozygous mutation (c.2014T > C p.Trp672Arg), and a novel homozygous mutation (c.16A > G p.Ile6Val) in the FGA gene were identified in two probands with dysfibrinogenemia. The global coagulation screening assay can distinguish four types of IFD, especially a ratio of Fib:Ag/Fib:C equal to 1.5, which can distinguish patients with hypofibrinogenemia from those with hypodysfibrinogenemia. A total of 81 mutations from 76 probands in 45 IFD families have been reported in the Chinese population. Arg35 in FGA and Arg301 in FGG were responsible for IFD in more than half of patients in the Chinese population. It is possible to distinguish four types of IFD by using a global coagulation screening assay. Mutations in FGA, FGB and FGG occur in different functional regions, and Arg changes account for more than 70% of patients with IFD in the Chinese population, especially Arg-Cys, which may be associated with severe clinical symptoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference De Moerloose P, Neerman-Arbez M (2009) Congenital fibrinogen disorders. Seminars in thrombosis and hemostasis. Thieme Medical Publishers, New York, pp 356–366 De Moerloose P, Neerman-Arbez M (2009) Congenital fibrinogen disorders. Seminars in thrombosis and hemostasis. Thieme Medical Publishers, New York, pp 356–366
2.
go back to reference Lefebvre P, Velasco PT, Dear A, Lounes KC, Lord ST, Brennan SO, Green D, Lorand L (2004) Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AαIVS4 + 1G > T mutation and an AαGln328 truncation (fibrinogen Keokuk). Blood 103(7):2571–2576CrossRef Lefebvre P, Velasco PT, Dear A, Lounes KC, Lord ST, Brennan SO, Green D, Lorand L (2004) Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AαIVS4 + 1G > T mutation and an AαGln328 truncation (fibrinogen Keokuk). Blood 103(7):2571–2576CrossRef
3.
go back to reference Kant JA, Fornace AJ, Saxe D, Simon MI, McBride OW, Crabtree GR (1985) Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 82(8):2344–2348CrossRef Kant JA, Fornace AJ, Saxe D, Simon MI, McBride OW, Crabtree GR (1985) Evolution and organization of the fibrinogen locus on chromosome 4: gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci USA 82(8):2344–2348CrossRef
4.
go back to reference Hanss M, Biot F (2001) A database for human fibrinogen variants. Ann N Y Acad Sci 936(1):89–90CrossRef Hanss M, Biot F (2001) A database for human fibrinogen variants. Ann N Y Acad Sci 936(1):89–90CrossRef
6.
go back to reference Le Quellec S, Desjonqueres A, Rugeri L, Clavel HD, Farhat F, Mechtouff L, Dargaud Y (2018) Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency. Thromb J 16(1):6CrossRef Le Quellec S, Desjonqueres A, Rugeri L, Clavel HD, Farhat F, Mechtouff L, Dargaud Y (2018) Combined life-threatening thromboses and hemorrhages in a patient with afibrinogenemia and antithrombin deficiency. Thromb J 16(1):6CrossRef
7.
go back to reference Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, Sakata Y (2006) A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 4(8):1738–1746CrossRef Sugo T, Endo H, Matsuda M, Ohmori T, Madoiwa S, Mimuro J, Sakata Y (2006) A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 4(8):1738–1746CrossRef
8.
go back to reference Flood VH, Al-Mondhiry HA, Farrell DH (2006) The fibrinogen Aα R16C mutation results in fibrinolytic resistance. Br J Haematol 134(2):220–226CrossRef Flood VH, Al-Mondhiry HA, Farrell DH (2006) The fibrinogen Aα R16C mutation results in fibrinolytic resistance. Br J Haematol 134(2):220–226CrossRef
9.
go back to reference Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, Cooper DN (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133(1):1–9CrossRef Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, Cooper DN (2014) The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 133(1):1–9CrossRef
10.
go back to reference Vitkup D, Sander C, Church GM (2003) The amino-acid mutational spectrum of human genetic disease. Genome Biol 4(11):R72CrossRef Vitkup D, Sander C, Church GM (2003) The amino-acid mutational spectrum of human genetic disease. Genome Biol 4(11):R72CrossRef
11.
go back to reference Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Gréen H, Lotfi K, Söderkvist P (2014) Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomarker Res 2(1):18CrossRef Willander K, Falk IJ, Chaireti R, Paul E, Hermansson M, Gréen H, Lotfi K, Söderkvist P (2014) Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomarker Res 2(1):18CrossRef
12.
go back to reference Haverkate F, Samama M (1995) Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 73(01):151–161CrossRef Haverkate F, Samama M (1995) Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 73(01):151–161CrossRef
Metadata
Title
Mutations in inherited fibrinogen disorders correlated with clinical features in the Chinese population
Authors
Yafang Wan
Tian Li
Wei Zhang
Liying Wang
Yu Zhang
Pu Liao
Shiqiang Liu
Publication date
01-05-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 4/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02283-5

Other articles of this Issue 4/2021

Journal of Thrombosis and Thrombolysis 4/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine